Status:
NO_LONGER_AVAILABLE
Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19
Lead Sponsor:
Jonathan Gerber
Conditions:
COVID
Sars-CoV2
Eligibility:
All Genders
12+ years
Brief Summary
The purpose of this program is to see if giving convalescent plasma to individuals who test positive for COVID-19 may reduce their symptoms and help minimize complications from the illness.
Detailed Description
As individuals are exposed to pathogens, the body's immune system works to create antibodies toward those pathogens. These antibodies can be found in the plasma portion of the blood. This plasma is re...
Eligibility Criteria
Inclusion
- At least 12 years of age
- Covid-19 Convalescent Plasma (CCP) treatment is in line with the patient's current goals of care (i.e. recipient cannot be DNI status)
- Laboratory confirmed diagnosis of infection with SARS-CoV-2 that is severe or life threatening OR the individual is judged by the treating provider to be at a high risk of progression to severe or life-threatening disease.
- Severe COVID-19 is defined by one or more of the following:
- Dyspnea
- Respiratory frequency ≥ 30/min
- Blood oxygen saturation ≤ 93%
- Partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300
- Lung infiltrates \> 50% within 24-48 hours
- Life-threatening COVID-19 is defined as one or more of the following:
- Respiratory failure
- Septic shock
- Multiple organ dysfunction or failure
Exclusion
- History of prior life-threatening reactions to transfusion of blood products
- Not receiving other therapies that would preclude plasma transfusion
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04445207
Last Update
May 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UMass Medical School
Worcester, Massachusetts, United States, 01655